Advancements in Understanding and Managing Pulmonary Thromboembolism and Hypertension

Thromboembolic and hypertensive disorders of the lungs, including pulmonary embolism (PE) and pulmonary hypertension (PH), represent critical areas in cardiovascular and respiratory medicine due to their complexity and the severe health risks they pose. Effective management of these conditions is complicated by their multifaceted impacts on pulmonary and circulatory function, necessitating advanced diagnostic techniques and nuanced therapeutic strategies. The integration of recent scientific advancements into clinical practice is vital for improving outcomes and understanding these serious conditions.

This Research Topic aims to compile and contextualize recent progress in the field of pulmonary vascular disorders, focusing on thromboembolic and hypertensive phenomena. It seeks to highlight new findings in the pathophysiology, diagnosis, and treatment of PE and PH, bringing together original research, comprehensive reviews, and case studies to provide a robust reference for ongoing clinical and research endeavors.

To foster advancements in the understanding and treatment of pulmonary embolism and hypertension, this Research Topic welcomes contributions that are not limited to but include the following themes:

o Molecular and cellular mechanisms implicated in the pathogenesis of PE and PH.
o The influence of genetic predispositions and environmental exposures on disease development.
o Cutting-edge imaging modalities and the role of biomarkers in early detection and patient stratification.
o Innovations in non-invasive diagnostic practices.
o Recent pharmacological developments and anticoagulation management approaches.
o New surgical and interventional strategies aimed at improving clinical outcomes.
o Detailed reports on unique case presentations and management challenges.
o Clinical trial results evaluating the efficacy of new treatment modalities.
o Research exploring novel therapeutic targets and personalized treatment plans.